Doxorubicin for favorable histology, Stage II–III Wilms tumor

After randomized trials in the 1980s, doxorubicin (DOX) was added to dactinomycin plus vincristine as standard chemotherapy for patients who had Stage III Wilms tumor (WT) of favorable histology (FH). Double‐agent chemotherapy was retained for patients with Stage II disease. In this study, the authors reevaluated the efficacy of DOX using extended follow‐up and additional patients.

[1]  N. Breslow,et al.  Congestive heart failure after treatment for Wilms' tumor: a report from the National Wilms' Tumor Study group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  R. Potter,et al.  Optimal duration of preoperative therapy in unilateral and nonmetastatic Wilms' tumor in children older than 6 months: results of the Ninth International Society of Pediatric Oncology Wilms' Tumor Trial and Study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  N. Breslow,et al.  Effect of duration of treatment on treatment outcome and cost of treatment for Wilms' tumor: a report from the National Wilms' Tumor Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  N. Breslow,et al.  Second malignant neoplasms following treatment for Wilm's tumor: a report from the National Wilms' Tumor Study Group. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  N. Breslow,et al.  The Effect of Chemotherapy Dose Intensity on the Hematological Toxicity of the Treatment for Wilms' Tumor: A Report from the National Wilms' Tumor Study , 1994, The American journal of pediatric hematology/oncology.

[6]  P. Voûte,et al.  Results of the Sixth International Society of Pediatric Oncology Wilms' Tumor Trial and Study: a risk-adapted therapeutic approach in Wilms' tumor. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  D. Green,et al.  Prognostic factors in nonmetastatic, favorable histology wilms' tumor. Results of the third national wilms' tumor study , 1991, Cancer.

[8]  Edward Baum,et al.  Treatment of Wilms' tumor. Results of the third national Wilms' tumor study , 1989, Cancer.

[9]  Y. Tsuchida,et al.  [Treatment of Wilms' tumor]. , 1983, Gan to kagaku ryoho. Cancer & chemotherapy.

[10]  L. Leape,et al.  The treatment of Wilms' Tumor: Results of the second national Wilms' Tumor study , 1981, Cancer.

[11]  E. Beckwith,et al.  Histopathology and prognosis of Wilms tumor Results from the first national wilms' tumor study , 1978, Cancer.

[12]  J. Ware,et al.  Randomized clinical trials. Perspectives on some recent ideas. , 1976, The New England journal of medicine.

[13]  J. Peto,et al.  Asymptotically Efficient Rank Invariant Test Procedures , 1972 .

[14]  N. Mantel.  Evaluation of survival data and two new rank order statistics arising in its consideration. , 1966, Cancer chemotherapy reports.

[15]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[16]  S. Wyard,et al.  THE NATURAL DURATION OF CANCER , 1925, Canadian Medical Association journal.

[17]  N E Breslow,et al.  Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  N. Breslow,et al.  Relationship between dose schedule and charges for treatment on National Wilms' Tumor Study-4. A report from the National Wilms' Tumor Study Group. , 1995, Journal of the National Cancer Institute. Monographs.

[19]  B. Camitta,et al.  Doxorubicin cardiomyopathy in children with left-sided Wilms tumor. , 1982, Medical and pediatric oncology.

[20]  David R. Cox,et al.  Regression models and life tables (with discussion , 1972 .

[21]  LONDON: HER MAJESTY'S STATIONERY OFFICE , 2022 .